Actively Recruiting
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
Led by VivaTech International, Inc. · Updated on 2025-10-14
4000
Participants Needed
1
Research Sites
578 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.
CONDITIONS
Official Title
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with indication of Osteoarthritis from degeneration or chronic injury
- Age between 18 and 90 years
- Able to follow treatment plan, laboratory tests, and periodic interviews
- Adequate kidney function (Creatinine 1.5 mg/dl)
- Adequate heart and lung function
- Adequate blood clotting activity (PT(INR) < 1.5, APTT)
- Adequate immune system function without known immunodeficiency
- Hip pain on the affected side lasting more than 6 months
You will not qualify if you...
- Cancer within 5 years prior to screening, except certain skin cancers resolved by excision
- Significant acute or unstable heart and brain blood vessel conditions
- Transient ischemic attack diagnosed within 6 months prior to screening
- Infection with hepatitis B, C, or HIV
- Body Mass Index over 40 kg/m2
- Active infection
- Illness, psychiatric disorder, or substance dependence making participation unsuitable
- Treatments or conditions affecting pain or mobility evaluation, including:
- Strong opioid use in last 4 weeks for pain other than hip osteoarthritis
- Corticosteroid injection at treatment site within 1 month
- Regular NSAID use within 48 hours before procedure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
VivaTech International, Inc.
Grove City, Pennsylvania, United States, 16127
Actively Recruiting
Research Team
S
Scott M Herkes, MBA
CONTACT
M
Michael P Hutchinson, DVM
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here